-
1
-
-
44849093562
-
Oncogene addiction
-
COI: 1:CAS:528:DC%2BD1cXltlSmtrk%3D, PID: 18451130
-
Weinstein IB, Joe A, Felsher D. Oncogene addiction. Cancer Res 2008; 68(9): 3077–3080, discussion 3080
-
(2008)
Cancer Res
, vol.68
, Issue.9
, pp. 3070-3077
-
-
Weinstein, I.B.1
Joe, A.2
Felsher, D.3
-
2
-
-
9244222261
-
Targeted cancer therapy
-
COI: 1:CAS:528:DC%2BD2cXpvVCjtL8%3D, PID: 15549090
-
Sawyers C. Targeted cancer therapy. Nature 2004; 432(7015): 294–297
-
(2004)
Nature
, vol.432
, Issue.7015
, pp. 294-297
-
-
Sawyers, C.1
-
3
-
-
77953896432
-
Cell signaling by receptor tyrosine kinases
-
COI: 1:CAS:528:DC%2BC3cXovFartb0%3D, PID: 20602996
-
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117–1134
-
(2010)
Cell
, vol.141
, Issue.7
, pp. 1117-1134
-
-
Lemmon, M.A.1
Schlessinger, J.2
-
4
-
-
84887497121
-
The quest to overcome resistance to EGFRtargeted therapies in cancer
-
COI: 1:CAS:528:DC%2BC3sXhslCmsLrP, PID: 24202392
-
Chong CR, Jänne PA. The quest to overcome resistance to EGFRtargeted therapies in cancer. Nat Med 2013; 19(11): 1389–1400
-
(2013)
Nat Med
, vol.19
, Issue.11
, pp. 1389-1400
-
-
Chong, C.R.1
Jänne, P.A.2
-
5
-
-
84884535896
-
Cancer drug resistance: an evolving paradigm
-
COI: 1:CAS:528:DC%2BC3sXhsVyqurnE, PID: 24060863
-
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13(10): 714–726
-
(2013)
Nat Rev Cancer
, vol.13
, Issue.10
, pp. 714-726
-
-
Holohan, C.1
Van Schaeybroeck, S.2
Longley, D.B.3
Johnston, P.G.4
-
6
-
-
84890018871
-
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
-
COI: 1:CAS:528:DC%2BC3sXhvVGrtrfE, PID: 24101047
-
Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31(31): 3987–3996
-
(2013)
J Clin Oncol
, vol.31
, Issue.31
, pp. 3987-3996
-
-
Gainor, J.F.1
Shaw, A.T.2
-
7
-
-
84913536390
-
Drug resistance to targeted therapies: déjà vu all over again
-
COI: 1:CAS:528:DC%2BC2cXhtVWrs7jP, PID: 24910388
-
Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol 2014; 8(6): 1067–1083
-
(2014)
Mol Oncol
, vol.8
, Issue.6
, pp. 1067-1083
-
-
Groenendijk, F.H.1
Bernards, R.2
-
8
-
-
84922781885
-
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
-
COI: 1:CAS:528:DC%2BC2cXhsV2ktLrF, PID: 25239057
-
Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014; 39(10): 465–474
-
(2014)
Trends Biochem Sci
, vol.39
, Issue.10
, pp. 465-474
-
-
Sun, C.1
Bernards, R.2
-
9
-
-
77951643141
-
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
-
COI: 1:CAS:528:DC%2BC3cXht1ynsbo%3D, PID: 20118985
-
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29(16): 2346–2356
-
(2010)
Oncogene
, vol.29
, Issue.16
, pp. 2346-2356
-
-
Ercan, D.1
Zejnullahu, K.2
Yonesaka, K.3
Xiao, Y.4
Capelletti, M.5
Rogers, A.6
Lifshits, E.7
Brown, A.8
Lee, C.9
Christensen, J.G.10
Kwiatkowski, D.J.11
Engelman, J.A.12
Jänne, P.A.13
-
10
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
PID: 21430269
-
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3(75): 75ra26
-
(2011)
Sci Transl Med
, vol.3
, Issue.75
, pp. 75ra26
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
Digumarthy, S.4
Turke, A.B.5
Fidias, P.6
Bergethon, K.7
Shaw, A.T.8
Gettinger, S.9
Cosper, A.K.10
Akhavanfard, S.11
Heist, R.S.12
Temel, J.13
Christensen, J.G.14
Wain, J.C.15
Lynch, T.J.16
Vernovsky, K.17
Mark, E.J.18
Lanuti, M.19
Iafrate, A.J.20
Mino-Kenudson, M.21
Engelman, J.A.22
more..
-
11
-
-
84856999699
-
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
-
PID: 22277784
-
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4(120): 120ra17
-
(2012)
Sci Transl Med
, vol.4
, Issue.120
, pp. 120ra17
-
-
Katayama, R.1
Shaw, A.T.2
Khan, T.M.3
Mino-Kenudson, M.4
Solomon, B.J.5
Halmos, B.6
Jessop, N.A.7
Wain, J.C.8
Yeo, A.T.9
Benes, C.10
Drew, L.11
Saeh, J.C.12
Crosby, K.13
Sequist, L.V.14
Iafrate, A.J.15
Engelman, J.A.16
-
12
-
-
84856990335
-
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC38Xjt1Wksro%3D, PID: 22235099
-
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18(5): 1472–1482
-
(2012)
Clin Cancer Res
, vol.18
, Issue.5
, pp. 1472-1482
-
-
Doebele, R.C.1
Pilling, A.B.2
Aisner, D.L.3
Kutateladze, T.G.4
Le, A.T.5
Weickhardt, A.J.6
Kondo, K.L.7
Linderman, D.J.8
Heasley, L.E.9
Franklin, W.A.10
Varella-Garcia, M.11
Camidge, D.R.12
-
13
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
COI: 1:CAS:528:DC%2BD1cXitl2mu7k%3D, PID: 18227510
-
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105(6): 2070–2075
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, Issue.6
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
Woo, M.S.4
Greulich, H.5
Wong, K.K.6
Meyerson, M.7
Eck, M.J.8
-
14
-
-
84885816283
-
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer
-
PID: 24065147
-
Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6(294): re6
-
(2013)
Sci Signal
, vol.6
, Issue.294
, pp. re6
-
-
Niederst, M.J.1
Engelman, J.A.2
-
15
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
COI: 1:CAS:528:DC%2BD2sXltlOjt7g%3D, PID: 17463250
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039–1043
-
(2007)
Science
, vol.316
, Issue.5827
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
Lindeman, N.7
Gale, C.M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
Rogers, A.M.13
Cappuzzo, F.14
Mok, T.15
Lee, C.16
Johnson, B.E.17
Cantley, L.C.18
Jänne, P.A.19
-
16
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
COI: 1:CAS:528:DC%2BD1cXktlyhsg%3D%3D, PID: 18093943
-
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104(52): 20932–20937
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.52
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
Riely, G.4
Viale, A.5
Wang, L.6
Chitale, D.7
Motoi, N.8
Szoke, J.9
Broderick, S.10
Balak, M.11
Chang, W.C.12
Yu, C.J.13
Gazdar, A.14
Pass, H.15
Rusch, V.16
Gerald, W.17
Huang, S.F.18
Yang, P.C.19
Miller, V.20
Ladanyi, M.21
Yang, C.H.22
Pao, W.23
more..
-
17
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
COI: 1:CAS:528:DC%2BD38XltVWluw%3D%3D, PID: 11752009
-
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24): 1852–1857
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.24
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
Mascarenhas, D.4
Pollak, M.5
-
18
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
COI: 1:CAS:528:DC%2BC38XhtFWjtLrO, PID: 22763448
-
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487(7408): 505–509
-
(2012)
Nature
, vol.487
, Issue.7408
, pp. 505-509
-
-
Wilson, T.R.1
Fridlyand, J.2
Yan, Y.3
Penuel, E.4
Burton, L.5
Chan, E.6
Peng, J.7
Lin, E.8
Wang, Y.9
Sosman, J.10
Ribas, A.11
Li, J.12
Moffat, J.13
Sutherlin, D.P.14
Koeppen, H.15
Merchant, M.16
Neve, R.17
Settleman, J.18
-
19
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
COI: 1:CAS:528:DC%2BC3cXkvFKgs7Y%3D, PID: 20129249
-
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17(1): 77–88
-
(2010)
Cancer Cell
, vol.17
, Issue.1
, pp. 77-88
-
-
Turke, A.B.1
Zejnullahu, K.2
Wu, Y.L.3
Song, Y.4
Dias-Santagata, D.5
Lifshits, E.6
Toschi, L.7
Rogers, A.8
Mok, T.9
Sequist, L.10
Lindeman, N.I.11
Murphy, C.12
Akhavanfard, S.13
Yeap, B.Y.14
Xiao, Y.15
Capelletti, M.16
Iafrate, A.J.17
Lee, C.18
Christensen, J.G.19
Engelman, J.A.20
Jänne, P.A.21
more..
-
20
-
-
84880886028
-
Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks
-
PID: 23861540
-
Wagner JP, Wolf-Yadlin A, Sevecka M, Grenier JK, Root DE, Lauffenburger DA, MacBeath G. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal 2013; 6(284): ra58
-
(2013)
Sci Signal
, vol.6
, Issue.284
, pp. ra58
-
-
Wagner, J.P.1
Wolf-Yadlin, A.2
Sevecka, M.3
Grenier, J.K.4
Root, D.E.5
Lauffenburger, D.A.6
MacBeath, G.7
-
21
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
COI: 1:CAS:528:DC%2BC3cXlsVSgtb8%3D, PID: 20371346
-
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141(1): 69–80
-
(2010)
Cell
, vol.141
, Issue.1
, pp. 69-80
-
-
Sharma, S.V.1
Lee, D.Y.2
Li, B.3
Quinlan, M.P.4
Takahashi, F.5
Maheswaran, S.6
McDermott, U.7
Azizian, N.8
Zou, L.9
Fischbach, M.A.10
Wong, K.K.11
Brandstetter, K.12
Wittner, B.13
Ramaswamy, S.14
Classon, M.15
Settleman, J.16
-
22
-
-
55949117661
-
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
-
COI: 1:CAS:528:DC%2BD1cXhtlelurrO, PID: 18948591
-
Grueneberg DA, Degot S, Pearlberg J, Li W, Davies JE, Baldwin A, Endege W, Doench J, Sawyer J, Hu Y, Boyce F, Xian J, Munger K, Harlow E. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci USA 2008; 105(43): 16472–16477
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, Issue.43
, pp. 16472-16477
-
-
Grueneberg, D.A.1
Degot, S.2
Pearlberg, J.3
Li, W.4
Davies, J.E.5
Baldwin, A.6
Endege, W.7
Doench, J.8
Sawyer, J.9
Hu, Y.10
Boyce, F.11
Xian, J.12
Munger, K.13
Harlow, E.14
-
23
-
-
73349129405
-
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
-
COI: 1:CAS:528:DC%2BD1MXhsFGitrzJ, PID: 19850869
-
Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 106(46): 19503–19508
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.46
, pp. 19503-19508
-
-
Faber, A.C.1
Li, D.2
Song, Y.3
Liang, M.C.4
Yeap, B.Y.5
Bronson, R.T.6
Lifshits, E.7
Chen, Z.8
Maira, S.M.9
García-Echeverría, C.10
Wong, K.K.11
Engelman, J.A.12
-
24
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
COI: 1:CAS:528:DC%2BC38XjtFOktb4%3D, PID: 22281684
-
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483(7387): 100–103
-
(2012)
Nature
, vol.483
, Issue.7387
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Di Nicolantonio, F.4
Salazar, R.5
Zecchin, D.6
Beijersbergen, R.L.7
Bardelli, A.8
Bernards, R.9
-
25
-
-
84883793323
-
RON confers lapatinib resistance in HER2-positive breast cancer cells
-
COI: 1:CAS:528:DC%2BC3sXhtFSmtrfK, PID: 23811285
-
Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett 2013; 340(1): 43–50
-
(2013)
Cancer Lett
, vol.340
, Issue.1
, pp. 43-50
-
-
Wang, Q.1
Quan, H.2
Zhao, J.3
Xie, C.4
Wang, L.5
Lou, L.6
-
26
-
-
37549061078
-
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
-
COI: 1:CAS:528:DC%2BD2sXhsVCjs7nL, PID: 18089823
-
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67(24): 11924–11932
-
(2007)
Cancer Res
, vol.67
, Issue.24
, pp. 11924-11932
-
-
Engelman, J.A.1
Zejnullahu, K.2
Gale, C.M.3
Lifshits, E.4
Gonzales, A.J.5
Shimamura, T.6
Zhao, F.7
Vincent, P.W.8
Naumov, G.N.9
Bradner, J.E.10
Althaus, I.W.11
Gandhi, L.12
Shapiro, G.I.13
Nelson, J.M.14
Heymach, J.V.15
Meyerson, M.16
Wong, K.K.17
Jänne, P.A.18
-
27
-
-
84920184506
-
EGF promotes mammalian cell growth by suppressing cellular senescence
-
COI: 1:CAS:528:DC%2BC2cXhvVOntLbL, PID: 25367123
-
Alexander PB, Yuan L, Yang P, Sun T, Chen R, Xiang H, Chen J, Wu H, Radiloff DR, Wang XF. EGF promotes mammalian cell growth by suppressing cellular senescence. Cell Res 2015; 25(1): 135–138
-
(2015)
Cell Res
, vol.25
, Issue.1
, pp. 135-138
-
-
Alexander, P.B.1
Yuan, L.2
Yang, P.3
Sun, T.4
Chen, R.5
Xiang, H.6
Chen, J.7
Wu, H.8
Radiloff, D.R.9
Wang, X.F.10
-
28
-
-
84873902360
-
Noncovalent wild-type-sparing inhibitors of EGFR T790M
-
COI: 1:CAS:528:DC%2BC3sXis1Wktrw%3D, PID: 23229345
-
Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov 2013; 3(2): 168–181
-
(2013)
Cancer Discov
, vol.3
, Issue.2
, pp. 168-181
-
-
Lee, H.J.1
Schaefer, G.2
Heffron, T.P.3
Shao, L.4
Ye, X.5
Sideris, S.6
Malek, S.7
Chan, E.8
Merchant, M.9
La, H.10
Ubhayakar, S.11
Yauch, R.L.12
Pirazzoli, V.13
Politi, K.14
Settleman, J.15
-
29
-
-
78049457409
-
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
-
COI: 1:CAS:528:DC%2BC3cXhtlCru73E, PID: 21031001
-
Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010; 9(11): 843–856
-
(2010)
Nat Rev Drug Discov
, vol.9
, Issue.11
, pp. 843-856
-
-
Kummar, S.1
Chen, H.X.2
Wright, J.3
Holbeck, S.4
Millin, M.D.5
Tomaszewski, J.6
Zweibel, J.7
Collins, J.8
Doroshow, J.H.9
-
30
-
-
84919443958
-
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
-
COI: 1:CAS:528:DC%2BC2cXitV2gtr3M, PID: 25394791
-
Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346(6216): 1480–1486
-
(2014)
Science
, vol.346
, Issue.6216
, pp. 1480-1486
-
-
Crystal, A.S.1
Shaw, A.T.2
Sequist, L.V.3
Friboulet, L.4
Niederst, M.J.5
Lockerman, E.L.6
Frias, R.L.7
Gainor, J.F.8
Amzallag, A.9
Greninger, P.10
Lee, D.11
Kalsy, A.12
Gomez-Caraballo, M.13
Elamine, L.14
Howe, E.15
Hur, W.16
Lifshits, E.17
Robinson, H.E.18
Katayama, R.19
Faber, A.C.20
Awad, M.M.21
Ramaswamy, S.22
Mino-Kenudson, M.23
Iafrate, A.J.24
Benes, C.H.25
Engelman, J.A.26
more..
|